Crestwood Advisors Group LLC Buys 1,384 Shares of Pfizer Inc. (NYSE:PFE)

Crestwood Advisors Group LLC lifted its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 4.3% during the first quarter, HoldingsChannel.com reports. The firm owned 33,693 shares of the biopharmaceutical company’s stock after purchasing an additional 1,384 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Pfizer were worth $1,744,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Econ Financial Services Corp bought a new stake in shares of Pfizer in the 4th quarter worth approximately $31,000. PYA Waltman Capital LLC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $31,000. Rinkey Investments bought a new stake in shares of Pfizer in the 4th quarter worth approximately $32,000. Stuart Chaussee & Associates Inc. boosted its position in shares of Pfizer by 108.3% in the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 325 shares in the last quarter. Finally, TFO TDC LLC lifted its position in Pfizer by 126.9% in the 4th quarter. TFO TDC LLC now owns 667 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 373 shares in the last quarter. 66.50% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PFE opened at $49.07 on Thursday. The company has a market cap of $275.33 billion, a price-to-earnings ratio of 11.25, a price-to-earnings-growth ratio of 0.56 and a beta of 0.76. Pfizer Inc. has a twelve month low of $38.82 and a twelve month high of $61.71. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $50.57 and a two-hundred day moving average of $52.22.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The company had revenue of $25.66 billion for the quarter, compared to analyst estimates of $24.73 billion. During the same quarter in the previous year, the firm posted $0.93 earnings per share. The company’s quarterly revenue was up 76.8% on a year-over-year basis. On average, sell-side analysts expect that Pfizer Inc. will post 6.61 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, June 10th. Investors of record on Friday, May 13th were given a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $1.60 dividend on an annualized basis and a yield of 3.26%. Pfizer’s payout ratio is presently 36.70%.

Several equities analysts recently issued reports on the company. SVB Leerink assumed coverage on Pfizer in a research report on Monday, May 23rd. They issued a “market perform” rating and a $55.00 price objective on the stock. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 19th. Barclays set a $52.00 target price on shares of Pfizer in a research note on Tuesday, May 17th. Morgan Stanley began coverage on shares of Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price for the company. Finally, The Goldman Sachs Group set a $51.00 target price on shares of Pfizer in a research note on Wednesday, May 25th. Nine equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $57.26.

In other Pfizer news, SVP Jennifer B. Damico sold 4,218 shares of the stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $53.96, for a total value of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction that occurred on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the completion of the sale, the executive vice president now directly owns 38,146 shares in the company, valued at $1,907,300. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock worth $2,075,003 over the last quarter. 0.05% of the stock is currently owned by company insiders.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.